A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

Meta-analysis of 64 clinical trials 'should give clinicians and their patients more confidence,' say Hopkins researchers ...

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Adults with overweight or obesity regained most weight lost during GLP-1 receptor agonist treatment at 1 year following cessation.

A large systematic review found that women lost, on average, 11% of their starting weight with GLP-1 receptor agonists, ...

Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

Popular GLP-1 receptor agonist drugs (GLP-1 RAs) for weight loss appear to be similarly effective among patients of different ages, races, and starting weight, with women benefiting somewhat more than ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...